Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot.
The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data.
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its GAAP loss of $2.52 per share was 18.6% above analysts’ consensus estimates.
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting other manufacturers.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 12.7%. This drop was worse than the S&P 500’s 7.5% loss.
